Gilead and Merck Report Results from the P-II Clinical Evaluation of Islatravir + Lenacapavir for HIV
Shots:
- The P-II trial assessed the safety & efficacy of islatravir (2mg, oral) + lenacapavir (300mg, QW) in virologically suppressed HIV patients (n=104, mean age: 40yrs.) on Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) at wk. 24
- The study showed a viral load of >50 c/mL in 1 patient, later suppressed at wk. 30, a 94.2% rate of viral suppression that was comparable with those continuing Biktarvy (94.2%) & none in the Biktarvy arm had a viral load of >50 c/mL
- The P-II trial will extend as an open-label study till wk. 48 with its longer-term results anticipated in the future scientific conferences
Ref: Gilead | Image: Gilead
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
